Anika Therapeutics (ANIK) Capital Expenditures Growth (5y) (2015 - 2026)
Anika Therapeutics (ANIK) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.71 Bn | 30.77 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.65 Bn | 23.59 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.18 Bn | 21.03 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - |
| 7 | Viatris | 20.30 Bn | 18.50 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.52 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 203.51 Mn | 136.72 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.35% |
| Dec 31, 2025 | 202.54% |
| Sep 30, 2025 | -37.56% |
| Jun 30, 2025 | 34.75% |
| Mar 31, 2025 | 55.62% |
| Dec 31, 2024 | -28.01% |
| Sep 30, 2024 | -20.57% |
| Jun 30, 2024 | 19.48% |
| Mar 31, 2024 | 20.38% |
| Dec 31, 2023 | 64.23% |
| Sep 30, 2023 | 72.58% |
| Jun 30, 2023 | -48.46% |
| Mar 31, 2023 | 46.33% |
| Dec 31, 2022 | 29.19% |
| Sep 30, 2022 | -17.30% |
| Jun 30, 2022 | -18.65% |
| Mar 31, 2022 | -8.62% |
| Dec 31, 2021 | 15.99% |
| Sep 30, 2021 | -34.29% |
| Jun 30, 2021 | 20.15% |